Published in Anticancer Res on December 11, 2003
A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients. Br J Cancer (2005) 1.61
Phase II study of sunitinib as second-line treatment for advanced gastric cancer. Invest New Drugs (2010) 1.25
Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum. Br J Cancer (2012) 1.17
Docetaxel: its role in current and future treatments for advanced gastric cancer. Gastric Cancer (2009) 1.00
Phase II study of capecitabine and cisplatin as first-line combination therapy in patients with gastric cancer recurrent after fluoropyrimidine-based adjuvant chemotherapy. Br J Cancer (2005) 0.94
Docetaxel, cisplatin and fluorouracil (DCF) regimen compared with non-taxane-containing palliative chemotherapy for gastric carcinoma: a systematic review and meta-analysis. PLoS One (2013) 0.93
FOXM1 mediates resistance to docetaxel in gastric cancer via up-regulating Stathmin. J Cell Mol Med (2014) 0.89
Forkhead box transcription factor 1 expression in gastric cancer: FOXM1 is a poor prognostic factor and mediates resistance to docetaxel. J Transl Med (2013) 0.87
Eastern Canadian Colorectal Cancer Consensus Conference: setting the limits of resectable disease. Curr Oncol (2010) 0.87
Second-line treatment of metastatic gastric cancer: Current options and future directions. World J Gastroenterol (2015) 0.86
Third-line docetaxel chemotherapy for recurrent and metastatic gastric cancer. Korean J Intern Med (2013) 0.86
Pharmacoethnicity of docetaxel-induced severe neutropenia: integrated analysis of published phase II and III trials. Int J Clin Oncol (2011) 0.84
Docetaxel and its potential in the treatment of refractory esophagogastric adenocarcinoma. Therap Adv Gastroenterol (2015) 0.80
Metastatic gastric cancer treatment: Second line and beyond. World J Gastroenterol (2016) 0.79
Mitomycin C and capecitabine in pretreated patients with metastatic gastric cancer: a multicenter phase II study. J Cancer Res Clin Oncol (2014) 0.75
Efficacy and safety study of docetaxel as salvage chemotherapy in metastatic gastric cancer failing fluoropyrimidine and platinum combination chemotherapy. Cancer Res Treat (2005) 0.75
Clinical benefits of combined chemotherapy with S-1, oxaliplatin, and docetaxel in advanced gastric cancer patients with palliative surgery. Onco Targets Ther (2016) 0.75
Docetaxel as salvage therapy in highly pretreated and drug resistant gastrointestinal carcinomas. Clin Med Oncol (2008) 0.75
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol (2012) 22.04
Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol (2005) 3.93
Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst (2003) 3.41
First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial. J Clin Oncol (2012) 3.04
Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. J Clin Oncol (2010) 2.69
Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials. Lancet Oncol (2005) 2.36
Definition of rapid virologic response with a highly sensitive real-time PCR-based HCV RNA assay in peginterferon alfa-2a plus ribavirin response-guided therapy. J Hepatol (2010) 2.35
Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer. J Clin Oncol (2009) 2.30
Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J Clin Oncol (2007) 2.19
Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res (2002) 2.01
Prognostic significance of epidermal growth factor receptor expression in colon cancer patients undergoing curative surgery. Ann Surg Oncol (2006) 2.01
Optimized granulocyte colony-stimulating factor prophylaxis in adult cancer patients: from biological principles to clinical guidelines. Expert Opin Ther Targets (2012) 1.99
Elevated perioperative serum vascular endothelial growth factor levels in patients with colon carcinoma. Cancer (2004) 1.90
Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. J Clin Oncol (2008) 1.61
Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study. Lancet Oncol (2007) 1.60
Quality of life, fatigue and depression in Italian long-term breast cancer survivors. Support Care Cancer (2012) 1.49
Cetuximab plus FOLFOX-4 in untreated patients with advanced colorectal cancer: a Gruppo Oncologico dell'Italia Meridionale Multicenter phase II study. Oncology (2011) 1.48
Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma. Cancer Treat Rev (2010) 1.45
Changes in CpG islands promoter methylation patterns during ductal breast carcinoma progression. Cancer Epidemiol Biomarkers Prev (2009) 1.43
A prospective study on survival in cancer patients with and without venous thromboembolism. Intern Emerg Med (2013) 1.42
miR-192/miR-215 influence 5-fluorouracil resistance through cell cycle-mediated mechanisms complementary to its post-transcriptional thymidilate synthase regulation. Mol Cancer Ther (2010) 1.42
Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial. J Clin Oncol (2011) 1.36
Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib. Oncologist (2010) 1.35
Prognostic significance of circulating IL-10 and IL-6 serum levels in colon cancer patients undergoing surgery. Clin Immunol (2002) 1.33
Epidemiological and clinical burden of chronic hepatitis B virus/hepatitis C virus infection. A multicenter Italian study. J Hepatol (2003) 1.32
Development of a second version of the Cobas AmpliPrep/Cobas TaqMan hepatitis C virus quantitative test with improved genotype inclusivity. J Clin Microbiol (2011) 1.29
Radiofrequency ablation of 40 lung neoplasms: preliminary results. AJR Am J Roentgenol (2004) 1.23
Anticancer oral therapy: emerging related issues. Cancer Treat Rev (2010) 1.17
Elevated serum levels of interleukin-8 in advanced non-small cell lung cancer patients: relationship with prognosis. J Interferon Cytokine Res (2002) 1.13
Frequent epigenetics inactivation of KEAP1 gene in non-small cell lung cancer. Epigenetics (2011) 1.12
Oral vinorelbine in the treatment of non-small cell lung cancer: rationale and implications for patient management. Drugs (2007) 1.07
Changes in miR-143 and miR-21 expression and clinicopathological correlations in pancreatic cancers. Pancreas (2012) 1.06
Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy: a prognostic score from individual data of nine randomised trials. Eur J Cancer (2010) 1.06
Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas. Cancer Treat Rev (2010) 1.05
Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management. Eur J Pain (2008) 1.04
Supportive care in patients with advanced non-small-cell lung cancer. Br J Cancer (2003) 1.04
Citrate anticoagulation in continuous venovenous hemodiafiltration: a metabolic challenge. Intensive Care Med (2002) 1.03
COBAS AmpliPrep-COBAS TaqMan hepatitis B virus (HBV) test: a novel automated real-time PCR assay for quantification of HBV DNA in plasma. J Clin Microbiol (2007) 1.02
High RAD51 mRNA expression characterize estrogen receptor-positive/progesteron receptor-negative breast cancer and is associated with patient's outcome. Int J Cancer (2010) 1.01
Target therapies in pancreatic carcinoma. Curr Med Chem (2014) 1.01
Replicative and transcriptional activities of hepatitis B virus in patients coinfected with hepatitis B and hepatitis delta viruses. J Virol (2010) 1.01
Topoisomerase-I, thymidylate synthase primary tumour expression and clinical efficacy of 5-FU/CPT-11 chemotherapy in advanced colorectal cancer patients. Int J Cancer (2004) 1.00
The effect of gefitinib (Iressa, ZD1839) in combination with oxaliplatin is schedule-dependent in colon cancer cell lines. Cancer Chemother Pharmacol (2003) 1.00
Preoperative chemoradiotherapy for squamous cell carcinoma and adenocarcinoma of the esophagus: a phase II study. Chest (2002) 1.00
Severe spontaneous acute tumor lysis syndrome and hypoglycemia in patient with germ cell tumor. Tumori (2011) 0.99
Psychological effects of cetuximab-induced cutaneous rash in advanced colorectal cancer patients. Support Care Cancer (2009) 0.98
Cancer patient-centered home care: a new model for health care in oncology. Ther Clin Risk Manag (2011) 0.97
Aberrant Keap1 methylation in breast cancer and association with clinicopathological features. Epigenetics (2012) 0.97
EGFR tyrosine kinases inhibitors in cancer treatment: in vitro and in vivo evidence. Front Biosci (Landmark Ed) (2011) 0.97
Synchronous presentation of B-cell chronic lymphocytic leukemia/small-cell lymphoma and colon adenocarcinoma within the same mesenteric lymph nodes and a single liver metastasis. J Clin Oncol (2010) 0.97
Retracted Circulating levels of interleukin-10 and interleukin-6 in gastric and colon cancer patients before and after surgery: relationship with radicality and outcome. J Interferon Cytokine Res (2002) 0.96
Natural history of malignant bone disease in gastric cancer: final results of a multicenter bone metastasis survey. PLoS One (2013) 0.95
Chemokine receptor CXCR4: role in gastrointestinal cancer. Crit Rev Oncol Hematol (2013) 0.95
Characterization of sequence-dependent synergy between ZD1839 ("Iressa") and oxaliplatin. Biochem Pharmacol (2003) 0.95
Clinical evaluation of the COBAS Ampliprep/COBAS TaqMan for HCV RNA quantitation in comparison with the branched-DNA assay. J Med Virol (2008) 0.94
Current status of targeted therapies in advanced gastric cancer. Expert Opin Ther Targets (2012) 0.94
Management of Skin Reactions During Cetuximab Treatment in Association With Chemotherapy or Radiotherapy: Update of the Italian Expert Recommendations. Am J Clin Oncol (2016) 0.93
Genomic instability and increased expression of BUB1B and MAD2L1 genes in ductal breast carcinoma. Cancer Lett (2007) 0.93
Irinotecan plus bolus/infusional 5-Fluorouracil and leucovorin in patients with pretreated advanced pancreatic carcinoma: a multicenter experience of the Gruppo Oncologico Italia Meridionale. Am J Clin Oncol (2010) 0.93
Role of colony stimulating factors (CSFs) in solid tumours: results of an expert panel. Crit Rev Oncol Hematol (2007) 0.92
Cost of insurance policies for investigator-initiated cancer clinical trials in Italy. Tumori (2005) 0.92
Alexithymia, coping, and illness behavior correlates of pain experience in cancer patients. Psychooncology (2007) 0.91
Three-month and long-term outcomes and their predictors in acute basilar artery occlusion treated with intra-arterial thrombolysis. Stroke (2011) 0.91
Metastatic melanoma: the new era of targeted therapy. Expert Opin Ther Targets (2012) 0.90
Randomized phase III trial of gemcitabine and cisplatin vs. gemcitabine alone in patients with advanced non-small cell lung cancer and a performance status of 2: the CAPPA-2 study. Lung Cancer (2013) 0.90
Informal caregiving burden in advanced non-small cell lung cancer: the HABIT study. J Thorac Oncol (2007) 0.89
Basal and bevacizumab-based therapy-induced changes of lactate dehydrogenases and fibrinogen levels and clinical outcome of previously untreated metastatic colorectal cancer patients: a multicentric retrospective analysis. Expert Opin Biol Ther (2014) 0.89
The long and winding road to useful predictive factors for anti-EGFR therapy in metastatic colorectal carcinoma: the KRAS/BRAF pathway. Oncology (2010) 0.89
Cetuximab and gemcitabine in elderly or adult PS2 patients with advanced non-small-cell lung cancer: The cetuximab in advanced lung cancer (CALC1-E and CALC1-PS2) randomized phase II trials. Lung Cancer (2010) 0.88
Effect of acceleration forces during transport through a pneumatic tube system on ROTEM® analysis. Clin Chem Lab Med (2012) 0.88
Irinotecan (CPT-11) and mitomycin-C (MMC) as second-line therapy in advanced gastric cancer: a phase II study of the Gruppo Oncologico dell' Italia Meridionale (prot. 2106). Am J Clin Oncol (2005) 0.88
Importance of adherence to guidelines in breast cancer clinical practice. The Italian experience (AIOM). Tumori (2011) 0.88
Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial. BMC Cancer (2006) 0.87
Unique case of giant adult paratesticular spindle cell rhabdomyosarcoma. Urology (2008) 0.87
First-line treatment with epirubicin and vinorelbine in metastatic breast cancer. J Clin Oncol (2002) 0.86
Evaluation of microRNA-10b prognostic significance in a prospective cohort of breast cancer patients. Mol Cancer (2014) 0.86
Basal cytokines profile in metastatic renal cell carcinoma patients treated with subcutaneous IL-2-based therapy compared with that of healthy donors. J Transl Med (2007) 0.86
CDC73 mutations and parafibromin immunohistochemistry in parathyroid tumors: clinical correlations in a single-centre patient cohort. Cell Oncol (Dordr) (2012) 0.85
Management of skin toxicity associated with cetuximab treatment in combination with chemotherapy or radiotherapy. Oncologist (2011) 0.85
Perspectives in adjuvant therapy of gastric cancer. Oncology (2010) 0.85
Single agent vinorelbine as first-line chemotherapy in elderly patients with advanced breast cancer. Anticancer Res (2003) 0.85
High specificity of quantitative methylation-specific PCR analysis for MGMT promoter hypermethylation detection in gliomas. J Biomed Biotechnol (2009) 0.84